UNSPSC 51273921: Bupivacaine/dextrose

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.

UNSPSC 51273921 Bupivacaine/dextrose is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and related delivery systems, though the solicitations posted under this code show substantial scope variation. State and local health departments, county government health services units, and cooperative purchasing alliances are the primary issuing bodies, with Seminole County, Florida, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) representing recent activity. The work being solicited ranges from naloxone and drug deactivation system procurement to broader generic pharmaceutical and over-the-counter product contracting through authorized wholesalers, suggesting the code captures both specialized pharmaceutical products and the wholesale distribution infrastructure that serves state and local health programs.

Geographic activity spans Florida, Texas, and Minnesota, with MMCAP's multi-state cooperative vehicle extending reach to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County's July 2026 IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the Texas HHS Commission's April 2026 Request for Information on direct-to-manufacturer prescription programs to inform future pharmacy benefit strategy; and MMCAP's March 2026 RFP for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026 and contract effectiveness set for July 1, 2026. The MMCAP solicitation requires submission through the ePro system, compliance with FDA requirements and the Drug Supply Chain Security Act, maintenance of relationships with authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), and comprehensive liability insurance including commercial general liability of $5,000,000 per occurrence.